[MOL] CMF tolerability and effectiveness reduced in older patientsfor ol [02390] Medicine On Line


[Date Prev][Date Next][Thread Prev][Thread Next][Date Index][Thread Index]

[MOL] CMF tolerability and effectiveness reduced in older patientsfor older patients



ABSTRACT: Burdens and Benefits of Adjuvant Cyclophosphamide,
Methotrexate,
    and Fluorouracil and Tamoxifen for Elderly Patients With Breast
    Cancer: The International Breast Cancer Study Group Trial VII
    [03/30/2000; Journal of Clinical Oncology]

PURPOSE: Information on the tolerability and efficacy of adjuvant
chemoendocrine therapy for older women is limited. We studied
these issues using the data collected as part of the International
Breast Cancer Study Group Trial VII. 

CONCLUSION: CMF tolerability and effectiveness were both reduced
for older patients compared with younger postmenopausal node-positive
breast cancer patients who received tamoxifen for 5 years. The
development and evaluation of less toxic and more effective chemotherapy
regimens are required for high-risk elderly patients. 

The full article can be found at:

http://www.jco.org/cgi/content/abstract/18/7/1412
------------------------------------------------------------------------
This is an automatically-generated notice.  If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------